Why the study?
CVD is the leading cause of illness burden in the Americas, and raised blood pressure causes over 50% of ischemic heart disease and stroke events globally, making effective identification and treatment of hypertension central to CVD prevention.
Effective identification and treatment of hypertension using validated automated devices is central to cardiovascular disease prevention in the Americas.
Non-validated BP devices may compromise hypertension care now; leaves open whether HEARTS regulatory strategies will ensure exclusive validated use by 2025.
Cardiovascular disease (CVD) is the leading cause of illness burden in the Americas, causing over 2 million deaths in 2017, a third of deaths overall for that year. While striking, CVD is threatening to have an even greater impact in the coming years based on the upward trend of the last decade [ 1 ]. Raised blood pressure (BP), a significant risk factor for the development of CVD, causes over 50% of ischemic heart disease and stroke events and 17% of total deaths globally [ 2 ]. The prevalence of hypertension (defined as SBP/DBP ≥140/90 mmHg or taking antihypertensive drugs) in Latin America and the Caribbean is 28% in women and 43% in men [ 3 ]. Thus, effective identification and treatment of hypertension is central to CVD prevention and decreasing CV morbidity and mortality [ 4 ].
No takes yet. Share an insight, caveat, or question.
Ordúñez et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: